title: Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia.
authors.forename: Eleni
authors.initials: E
authors.lastname: Tholouli
authors.forename: Effie
authors.initials: E
authors.lastname: Liakopoulou
authors.forename: Hayley M
authors.initials: HM
authors.lastname: Greenfield
authors.forename: Bronwen E
authors.initials: BE
authors.lastname: Shaw
authors.forename: Sudhir
authors.initials: S
authors.lastname: Tauro
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Byrne
authors.forename: Mike
authors.initials: M
authors.lastname: Dennis
authors.forename: John
authors.initials: J
authors.lastname: Burthem
authors.forename: Guy S
authors.initials: GS
authors.lastname: Lucas
authors.forename: Charles
authors.initials: C
authors.lastname: Craddock
authors.forename: Nigel H
authors.initials: NH
authors.lastname: Russell
authors.forename: John A
authors.initials: JA
authors.lastname: Liu Yin
mesh_terms: D000328:Adult; D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D012008:Recurrence; D033581:Stem Cell Transplantation / Q000379:methods*; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab